Listen to the article
Andrew Wirmani, a partner at Reese Marketos LLP, has established himself as a formidable force in healthcare litigation, earning recognition as one of Law360’s Healthcare MVPs for 2025.
The Dallas-based attorney’s selection comes after a year of remarkable achievements in False Claims Act litigation, including his instrumental role in securing a record-breaking judgment against pharmaceutical giant Janssen Products, a Johnson & Johnson subsidiary. Details of the landmark case reveal Wirmani’s skill in navigating complex healthcare fraud litigation and his ability to build compelling cases against major industry players.
In addition to the Janssen victory, Wirmani successfully negotiated a $100 million settlement with PharMerica, one of the nation’s largest providers of pharmacy services to long-term care facilities. The settlement resolved allegations that PharMerica had engaged in improper billing practices and violations of federal healthcare regulations.
Industry observers note that these cases reflect a growing trend of aggressive enforcement in the healthcare sector, particularly targeting pharmaceutical companies and service providers that bill federal healthcare programs like Medicare and Medicaid. The Department of Justice has increasingly prioritized healthcare fraud cases, with recoveries totaling billions annually.
Wirmani’s expertise in the healthcare sector has been developed over years of focused practice. At Reese Marketos, he leads the firm’s healthcare practice, specializing in complex fraud cases and whistleblower litigation. His approach combines thorough investigative work with strategic litigation tactics, allowing him to take on powerful corporate defendants.
“False Claims Act cases require extraordinary patience and attention to detail,” noted a healthcare compliance expert familiar with Wirmani’s work. “The fact that he’s secured both a record judgment and a nine-figure settlement speaks volumes about his capabilities in this specialized area.”
The implications of Wirmani’s recent victories extend beyond the immediate financial penalties imposed on the companies involved. Such high-profile cases often trigger industry-wide compliance reviews and can influence corporate behavior throughout the healthcare ecosystem. Pharmaceutical companies and healthcare service providers are increasingly investing in robust compliance programs to mitigate similar legal risks.
Whistleblower protections under the False Claims Act have encouraged insiders to come forward with information about potential fraud, creating a pipeline of cases for attorneys like Wirmani. These qui tam provisions allow whistleblowers to share in any financial recovery, providing powerful incentives for reporting misconduct.
The healthcare sector remains particularly vulnerable to fraud allegations due to its complex billing systems, extensive regulations, and the substantial federal dollars at stake. Medicare and Medicaid fraud alone cost taxpayers billions annually, making successful enforcement actions critical to protecting public resources.
Law360’s MVP recognition highlights attorneys who have achieved exceptional results in their respective practice areas. The selection process considers the significance of cases handled, the complexity of legal issues addressed, and the impact of outcomes on the broader legal landscape.
For Wirmani, the recognition comes at a time when healthcare fraud enforcement continues to evolve, with new theories of liability emerging and regulatory requirements becoming increasingly stringent. His success demonstrates the potential for private attorneys, often working alongside government prosecutors, to play a significant role in combating healthcare fraud.
As federal healthcare spending continues to rise, the work of attorneys specializing in False Claims Act litigation is likely to remain critical to ensuring program integrity and accountability among healthcare providers and pharmaceutical manufacturers.
The healthcare industry will be watching closely to see how Wirmani and his firm build upon these recent successes in the coming year, potentially setting new precedents in healthcare fraud litigation.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
11 Comments
The healthcare sector is rife with opportunities for fraud and abuse, but it’s encouraging to see attorneys like Wirmani stepping up to hold companies accountable. These record-breaking judgments and settlements send a clear message that such behavior will not be tolerated. Continued vigilance and enforcement is critical to protecting taxpayer-funded programs and maintaining public trust.
Absolutely. Fraud and improper billing practices divert critical resources away from the patients and communities who need them most. Aggressive enforcement is essential to ensure the healthcare system operates with integrity and in the public interest.
The healthcare industry is notoriously complex, but that’s no excuse for blatant fraud and regulatory violations. Wirmani’s success in these cases demonstrates the value of skilled litigators who are willing to take on even the largest and most powerful industry players. This type of enforcement is crucial to maintaining the integrity of federal healthcare programs.
Impressive work by Andrew Wirmani in these healthcare fraud cases. Securing record-breaking judgments and multi-million dollar settlements against major industry players is no easy feat. This type of aggressive enforcement is clearly needed to rein in questionable billing practices and regulatory violations in the healthcare sector.
Agreed, these cases demonstrate the importance of rigorous oversight and accountability in the healthcare industry. Whistleblowers and skilled litigators like Wirmani play a critical role in uncovering and addressing systemic fraud.
It’s good to see the government taking a tough stance on healthcare fraud. Janssen Products and PharMerica need to be held accountable for their improper actions that waste taxpayer money and undermine the integrity of federal healthcare programs. More of these high-profile cases would send a strong message to the industry.
Absolutely. Healthcare fraud drains resources from programs that provide critical services to vulnerable populations. Aggressive enforcement is crucial to deter such unethical practices and protect the public interest.
These cases demonstrate the importance of empowering whistleblowers and skilled litigators to combat fraud in the healthcare industry. The sums involved are staggering, and the impact on public programs can be devastating. Wirmani’s track record is truly impressive and should serve as a warning to others considering unethical practices.
The healthcare sector has long been plagued by questionable billing and regulatory violations. These cases highlight the need for continued vigilance and a willingness to take on even the largest industry players. Wirmani’s success in securing such substantial penalties is an encouraging sign that the tide may be turning.
While the details of these cases are complex, the bottom line is clear – major healthcare companies were caught defrauding the system and need to be held accountable. Kudos to Wirmani and his team for their diligent work in uncovering these schemes and delivering meaningful consequences.
Yes, it’s critical that the justice system maintains a strong stance against healthcare fraud. Taxpayer-funded programs must be protected from abuse, and these high-profile cases serve as an important deterrent.